Nuvation Bio's Supplemental NDA With Updated Data For IBTROZI Wins FDA Acceptance

Nuvation Bio said the FDA accepted its supplemental New Drug Application for IBTROZI in advanced ROS1-positive non-small cell lung cancer, a regulatory step that keeps the drug’s review process on track. The update is positive for the company, but the article does not include an approval decision or detailed efficacy data. Market impact should be limited unless the FDA later grants approval.

Analysis

Nuvation Bio said the FDA accepted its supplemental New Drug Application for IBTROZI in advanced ROS1-positive non-small cell lung cancer, a regulatory step that keeps the drug’s review process on track. The update is positive for the company, but the article does not include an approval decision or detailed efficacy data. Market impact should be limited unless the FDA later grants approval.